Baader Bank Aktiengesellschaft Takes Position in Ionis Pharmaceuticals, Inc. $IONS

Baader Bank Aktiengesellschaft acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, HoldingsChannel.com reports. The firm acquired 10,228 shares of the company’s stock, valued at approximately $668,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. grew its holdings in Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock valued at $150,138,000 after buying an additional 2,724,400 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Ionis Pharmaceuticals by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,891,095 shares of the company’s stock valued at $114,245,000 after acquiring an additional 48,141 shares during the last quarter. Groupama Asset Managment grew its holdings in shares of Ionis Pharmaceuticals by 8.6% in the second quarter. Groupama Asset Managment now owns 1,160,957 shares of the company’s stock valued at $45,869,000 after purchasing an additional 91,746 shares during the period. TD Asset Management Inc grew its holdings in shares of Ionis Pharmaceuticals by 0.4% in the second quarter. TD Asset Management Inc now owns 1,104,690 shares of the company’s stock valued at $43,646,000 after purchasing an additional 4,224 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in Ionis Pharmaceuticals by 66.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 862,593 shares of the company’s stock worth $56,431,000 after purchasing an additional 343,409 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Joseph H. Wender sold 28,000 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the transaction, the director directly owned 36,035 shares of the company’s stock, valued at $2,912,348.70. The trade was a 43.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Swayze sold 23,463 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $79.12, for a total value of $1,856,392.56. Following the sale, the executive vice president owned 30,453 shares in the company, valued at approximately $2,409,441.36. This trade represents a 43.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 460,714 shares of company stock valued at $37,295,131 in the last 90 days. Insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IONS. Needham & Company LLC boosted their target price on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on Ionis Pharmaceuticals from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Bank of America lifted their target price on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Piper Sandler upped their price target on Ionis Pharmaceuticals from $77.00 to $87.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $86.95.

Ionis Pharmaceuticals Trading Up 0.1%

Shares of IONS stock opened at $84.35 on Thursday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $86.74. The stock has a market capitalization of $13.66 billion, a P/E ratio of -49.91 and a beta of 0.29. The company has a 50 day moving average price of $80.72 and a 200 day moving average price of $68.75.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.